Severe Hyperlipidemia in Apolipoprotein E2 Homozygotes Due to a Combined Effect of Hyperinsulinemia and an Sst I Polymorphism
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Abstract —More than 90% of patients with type III hyperlipoproteinemia are homozygous carriers of the apolipoprotein (apo) E*2 allele. The great majority of these apoE2(Arg158→Cys) homozygotes in the general population, however, are normolipidemic. Apparently, expression of the hyperlipidemic state requires additional genetic and/or environmental factors, suggesting a multifactorial etiology. To elucidate these additional risk factors, we analyzed normolipidemic and hyperlipidemic apoE2 homozygotes. Hyperinsulinemia was observed in 27 of 49 apoE2 homozygotes and associated with elevated lipid levels: hyperinsulinemic apoE2 homozygotes had type III hyperlipoproteinemia 6 times more often than apoE2 homozygotes with normal insulin levels (odds ratio 6.2, P =0.02). We screened the normolipidemic and hyperlipidemic apoE2 homozygotes for common variants in candidate genes involved in lipolysis—the APOA1-C3-A4 gene cluster, lipoprotein lipase, and hepatic lipase—and analyzed for associations with the expression of hyperlipidemia. In the hyperinsulinemic group, the 7 carriers of the Sst I polymorphism (S2) in the APOC3 gene displayed severely elevated VLDL cholesterol ( P insulin by Sst I <0.001) and VLDL triglyceride ( P insulin by Sst I <0.01) and low levels of HDL ( P insulin by Sst I <0.02). In the normoinsulinemic group, no such relation of the Sst I polymorphism with hyperlipidemia was observed. These data provide the first evidence for a combined effect of hyperinsulinemia and the Sst I polymorphism on the expression of hyperlipidemia in apoE2 homozygotes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
How good a marker is insulin level for insulin resistance?
Laakso, M. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116768 · Cited by 726
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man
UTERMANN, G., HEES, M., & STEINMETZ, A. (1977) · Nature · doi:10.1038/269604a0 · Cited by 666
Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects.
Kolterman, O. G., Insel, J., Saekow, M., & Olefsky, J. M. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109790 · Cited by 664
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278
Innerarity, T. L., Weisgraber, K. H., Arnold, K. S., Rall, S. C., & Mahley, R. W. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39866-6 · Cited by 179 · cited 1×
“dyslipidemia17–20; (2) HL activity is much less stimulated by apoE2 than by apoE3 21; (3) apoC3 inhibits LPL22 and reduces the hepatic uptake of triglyceride-rich remnant particles 23,24; (4) in mice, apoC3 was shown to decrease the lipolysis at the cell surfaces 25; and (5) in various human populations, the SstI poly…”
BackgroundSmit, M., de Knijff, P., Rosseneu, M., Bury, J., Klasen, E., Frants, R., & Havekes, L. (1988) · Human Genetics · doi:10.1007/bf01790099 · Cited by 127
Self-citation
Cited by
A large electronic-health-record-based genome-wide study of serum lipids
Hoffmann, T. J., Theusch, E., Haldar, T., Ranatunga, D. K., Jorgenson, E., Medina, M. W., Kvale, M. N., Kwok, P.-Y., Schaefer, C., Krauss, R. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0064-5 · Cited by 297
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
Shachter, N. S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00009 · Cited by 288
de Beer, F., Stalenhoef, A. F. H., Hoogerbrugge, N., Kastelein, J. J. P., Gevers Leuven, J. A., van Duijn, C. M., Havekes, L. M., & Smelt, A. H. M. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0202.102919 · Cited by 74
“Antihypertensive drugs 3 (5) 62 26 (20)‡ 132”
Self-citationKoopal, C., Marais, A. D., Westerink, J., & Visseren, F. L. J. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.10.001 · Cited by 53
Heidemann, B. E., Wolters, F. J., Kavousi, M., Gruppen, E. G., Dullaart, R. P., Marais, A. D., Visseren, F. L., & Koopal, C. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.001 · Cited by 21
Metadata
- Authors
- Sijbrands, E. J. G., Hoffer, M. J. V., Meinders, A. E., Havekes, L. M., Frants, R. R., Smelt, A. H. M., & De Knijff, P.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1999-11
- Volume
- 19
- Issue
- 11
- Pages
- 2722-2729
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2127226744
- Cited by
- 33
- References
- 9
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Severe Hyperlipidemia in Apolipoprotein E2 Homozygotes Due to a Combined Effect of Hyperinsulinemia and an Sst I Polymorphism. https://app.cochat.ai/papers/10.1161/01.atv.19.11.2722
- The paper
- Sijbrands, E. J. G., Hoffer, M. J. V., Meinders, A. E., Havekes, L. M., Frants, R. R., Smelt, A. H. M., & De Knijff, P. (1999). Severe Hyperlipidemia in Apolipoprotein E2 Homozygotes Due to a Combined Effect of Hyperinsulinemia and an Sst I Polymorphism. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.19.11.2722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.